Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 HKEX Manufacturing
Filings indexed 356 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVES
Regulatory Filings
2026-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings
2026-05-06 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-29 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-29 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Stock Exchange, detailing movements in authorised/issued share capital, share options, treasury shares, and public float sufficiency under Listing Rule Chapter 19B. It is not announcing a one‐off capital change per se (e.g., new issue or stock split), nor is it an earnings release, annual report, or investor presentation. Instead, it is a periodic regulatory compliance filing. Therefore it should be classified under Regulatory Filings (fallback category).
2026-04-08 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is titled “Announcement of Annual Results for the Year Ended December 31, 2025” and contains financial highlights, audited consolidated statements of profit or loss, statements of financial position, and notes. It is the initial publication of the company’s full-year financial results rather than the complete statutory annual report. This matches the definition of an Earnings Release (ER), which is the announcement of periodic financial results. FY 2025
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.